Erratum to: clinical effects of tramiprosate in apoe4/4 homozygous patients with mild alzheimer’s disease suggest disease modification potential

Abushakra, S.; Porsteinsson, A.; Scheltens, P.; Sadowsky, C.; Vellas, B.; Cummings, J.; Gauthier, S.; Hey, J.A.; Power, A.; Wang, P.; Shen, L.; Tolar, M.

Archives

journal articles

ERRATUM TO: CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL

S. Abushakra, A. Porsteinsson, P. Scheltens, C. Sadowsky, B. Vellas, J. Cummings, S. Gauthier, J.A. Hey, A. Power, P. Wang, L. Shen, M. Tolar

J Prev Alz Dis 2024;1(11):264

CITATION:
S. Abushakra ; A. Porsteinsson ; P. Scheltens ; C. Sadowsky ; B. Vellas ; J. Cummings ; S. Gauthier ; J.A. Hey ; A. Power ; P. Wang ; L. Shen ; M. Tolar ; (2024): Erratum to: Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2024.14

Download PDF View HTML